Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
US Open: NFP Has Shifted Fed Expectations, and Wall Street Now Awaits Inflation
ASML is picking up pace again.
Novartis shares fall the most since 2020 📉 What is behind the 10% decline?
Market Wrap: Far-right AfD wins in Germany, oil continues to rise (07.09.2026)